Perioperative Chemotherapy Combined With HIPEC for High-risk Advanced Gastric Cancer

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators intend to conduct a randomized controlled study to find if combining HIPEC (hyperthermic intraperitoneal perfusion chemotherapy) with post-neoadjuvant chemotherapy D2 resection could improve survival for patients with advanced gastric cancer, while comparing with the traditional approach of D2 resection after neoadjuvant chemotherapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

Criteria

Inclusion Criteria:

1. First diagnosed as gastric cancer by pathological examination;

2. No previous chemotherapy or radiotherapy;

3. T stage:3-4, N stage: 1-3, M stage: 0, assessed by CT or ultrasound endoscope;

4. Eastern Cooperative Oncology Group performance status (ECOG PS): 0-1;

5. Informed consent signed;

Exclusion Criteria:

1. Other malignancy within 5 years.

2. Peritoneal metastasis detected during surgery.

3. Pregnant or lactating women;

4. Patients with conditions requiring emergency surgery;

5. Tumor progress during neo-adjuvant chemotherapy

6. Severe, uncontrolled physical or metal disease.

7. Poor compliance.

8. Uncontrolled infection